Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025

Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications.

View Full Paper
Ask AI
Bookmark
Share

Authors

ECElena-Christen CreangăRSRaluca StanANAlina Nicolae

Discussion

Loading...

Member takes

Overview

This review explores erythropoietin’s role in anemia treatment and its implications for precision medicine.

Key Points

  • Erythropoietin therapy shows promise in managing anemia, particularly among patients with chronic kidney disease.
  • Current findings stress the importance of understanding pharmacokinetics and molecular mechanisms of recombinant human EPO.
  • Novel agents like HIF-prolyl hydroxylase inhibitors expand the potential applications of EPO in various clinical settings.
  • Research highlights risks associated with EPO therapy, including cardiovascular complications and doping concerns.

Cite This Study

Creangă et al. (2025) studied this question.

synapsesocial.com/papers/68da58d1c1728099cfd10cdchttps://doi.org/10.3390/pharmaceutics17091190
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The purpose and effectiveness of doping testing in sport2024 · 15 citations
  2. 2Polypharmacy in the Management of Arterial Hypertension—Friend or Foe?2021 · 49 citations
  3. 3Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver2021 · 19 citations
  4. 4Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis2024 · 6 citations
  5. 5Modified recombinant human erythropoietin with potentially reduced immunogenicity2021 · 10 citations